New pill aims to take the edge off quitting weed
NCT ID NCT07644052
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medication called PP-01 to help adults with cannabis use disorder manage withdrawal symptoms when they stop using cannabis. About 420 participants will receive PP-01, an existing drug (nabilone), or a placebo daily for 34 days, with a one-week hospital stay at the start. The goal is to see if PP-01 reduces symptoms like irritability and sleep trouble better than placebo or nabilone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PP-01 (a combination product that partially activates cannabinoid receptors and modulates GABA)
What this could lead to
If successful, this could provide a new medication to help people quit cannabis by reducing withdrawal symptoms like irritability and sleep problems.
What could go wrong
This is a Phase 3 trial, but it's still experimental. The drug may not work better than placebo or existing treatments, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANNABIS USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AMR Clinical
RECRUITINGKnoxville, Tennessee, 37920, United States
Contact
-
CenExel iResearch, LLC
RECRUITINGSavannah, Georgia, 31405, United States
Contact
-
ForCare Clinical Research
RECRUITINGTampa, Florida, 33613, United States
Contact
-
Hassman Research Institute, LLC d/b/a CenExel Marlton, NJ
RECRUITINGMarlton, New Jersey, 08053, United States
Contact
-
Neuro-Behavioral Clinical Research, Inc.
RECRUITINGNorth Canton, Ohio, 44720, United States
Contact
-
Research Centers of America
RECRUITINGHollywood, Florida, 33024, United States
Contact
-
Richmond Behavioral Associates
RECRUITINGStaten Island, New York, 10314, United States
Contact
-
Sandhill Research, LLC d/b/a Accel Research Sites - NeuroStudies Clinical Research Unit 755
RECRUITINGLargo, Florida, 33777, United States
Contact
-
Sandhill Research, LLC d/b/a Accel Research Sites - NeuroStudies Clinical Research Unit 755
RECRUITINGDecatur, Georgia, 30030, United States
Contact
-
University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - DeLand Clinical Research Unit
RECRUITINGDeLand, Florida, 32720, United States
Contact